Tower Research Capital (TRC)’s Gain Therapeutics GANX Stock Holding History
Bought
Maintained
Sold
Other funds holding GANX
PCM
Tower Research Capital (TRC)'s GANX Position: Q3 2026 in Review
Tower Research Capital (TRC) reduced its Gain Therapeutics (GANX) stake by 43% in Q3 2026, selling an estimated $6.56K and leaving 4,728 shares worth $8.18K. The position accounts for ﹤0.01% of the portfolio, ranked #4424.
Tower Research Capital (TRC) first reported a position in GANX in Q2 2021 and has held it in 21 quarters since. The position peaked at $33K in Q1 2023. 50 funds tracked by Wall St. Rank hold GANX as of Q3 2026.
- Tower Research Capital (TRC) held 4,728 shares of Gain Therapeutics worth $8.18K as of Q3 2026.
- Tower Research Capital (TRC) sold 3,593 Gain Therapeutics shares in Q3 2026, an estimated $6.56K.
- Gain Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #4424 holding.
- Tower Research Capital (TRC) first reported a position in Gain Therapeutics in Q2 2021 and has held it in 21 quarters since.
- Tower Research Capital (TRC)'s Gain Therapeutics position peaked at $33K in Q1 2023.
- 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q3 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.